Seeking Alpha
  • Todd Johnson
    $EXEL disagrees with FDA, and decides they will continue with 306 study on its own terms. Not a sound business model...
    11/1/11
    Reply (1)
    • TruffelPig: A bit oversimplified what you write there.
      12/5/11